Align Financial’s Biogen BIIB Stock Holding History

Align Financial’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.05K	Hold	28	–	–	﹤0.01%	286
2026 Q1	$5.13K	Sell	28 -4,900	-99%	-$903K	﹤0.01%	299
2025 Q4	$4.93K	Buy	+4,928	New	+$805K	﹤0.01%	319

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Align Financial's BIIB Position: Q2 2026 in Review

Align Financial held its Biogen (BIIB) position steady in Q2 2026 at 28 shares worth $6.05K. The position accounts for ﹤0.01% of the portfolio, ranked #286.

Align Financial first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Align Financial held 28 shares of Biogen worth $6.05K as of Q2 2026.
Align Financial left its Biogen share count unchanged in Q2 2026.
Biogen made up ﹤0.01% of Align Financial's portfolio in Q2 2026, its #286 holding.
Align Financial first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Align Financial's 13F filing for Q2 2026, filed 27 Jul 2026.